Compare SIBN & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIBN | VALN |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.4M | 875.7M |
| IPO Year | 2018 | 2021 |
| Metric | SIBN | VALN |
|---|---|---|
| Price | $12.92 | $6.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $24.13 | $15.75 |
| AVG Volume (30 Days) | ★ 517.2K | 78.1K |
| Earning Date | 05-04-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,301,000.00 | N/A |
| Revenue This Year | $16.95 | $4.00 |
| Revenue Next Year | $14.93 | $92.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.53 | N/A |
| 52 Week Low | $12.50 | $5.43 |
| 52 Week High | $21.89 | $12.25 |
| Indicator | SIBN | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 25.90 |
| Support Level | N/A | $5.69 |
| Resistance Level | $14.24 | $6.73 |
| Average True Range (ATR) | 0.64 | 0.42 |
| MACD | 0.04 | -0.57 |
| Stochastic Oscillator | 28.94 | 1.75 |
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.